Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo

Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab antibody-drug conjugates. To expand the options, bispe...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Zheng Wang (Author), Yu Liu (Author), Yunxia Xu (Author), Lin Lu (Author), Zhen Zhu (Author), Baojie Lv (Author), Xin Fang (Author), Yao Tang (Author), Jinhua Wang (Author), Yu Cheng (Author), Ying Hu (Author), Junwen Lou (Author), Peican Wu (Author), Chendan Liu (Author), Yanjun Liu (Author), Xin Zeng (Author), Qing Xu (Author)
Hōputu: Pukapuka
I whakaputaina: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Ngā marau:
Urunga tuihono:Connect to this object online.
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ipurangi

Connect to this object online.

3rd Floor Main Library

Ngā taipitopito puringa mai i 3rd Floor Main Library
Tau karanga: A1234.567
Tārua 1 Wātea